United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Nearly four months ago I wrote that should the Covid-19 vaccine being developed by Pfizer Inc. (NYSE:PFE) prove successful, it could generate revenue of $15 billion. That expectation is moving closer to reality after the New York-based pharmaceutical leader and partner BioNTech SE (NASDAQ:BNTX) announced on Monday their leading candidate worked 90% of the time.

Sales of Pfizer's Covid Vaccine Could Hit $4.6 Billion in 2021

Pfizer (NYSE:PFE) plans to distribute its potential COVID-19 vaccine directly to the locations where it will be administered in Canada in specialized, temperature-controlled containers filled with dry ice under a “flexible just-in-time” logistics scheme, the company said. The pharmaceutical giant is developing its Canadian distribution plan with federal and provincial government agencies to deploy the vaccine in the event it is approved for use.

Pfizer plans ‘just-in-time' COVID-19 vaccine distribution in Canada

Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis

Pfizer and BioNTech could make $13bn from coronavirus vaccine

Pfizer (NYSE: PFE) and its German partner BioNTech indicated that their Coronavirus vaccine, dubbed BNT162b2, was over 90% effective at preventing Covid-19 infections among volunteers, based on early data from phase 3 trials.

Why Pfizer's Covid-19 Vaccine Is Unlikely To Move The Needle For The Stock

Election Outcome Boosted Risk-On Theme Last Week One headline changes the narrative about the pandemic; or does it? Pfizer's vaccine study results Monday morning are shockingly good with over 90% effectiveness in preventing infection.

Pfizer Vaccine Puts a Return to Normal Within Reach in 2021

When pharmaceutical company Pfizer announced Monday its experimental coronavirus vaccine may be 90% effective, many questions remained, including when it may be available and for whom. On Tuesday's episode of the Today Show, Secretary of Health and Human Services Alex Azar addressed those questions, saying the general public should have access to the vaccine and potentially others, like one in development by Moderna, by the end of March and early April 2021.

Health secretary Alex Azar said Pfizer's coronavirus vaccine will be available to 'all Americans' by April

Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate. The Pfizer Analysts: Morgan Stanley analyst David Risinger has an Equal-weight rating on Pfizer with a $42 price target.

Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%

Alphabet

Eli Lilly

The last time we saw the Dow surge strongly ahead while the Nasdaq dipped into the red was back in 2000, when the tech bubble of the pre-Y2K market began to burst.

Blue Chips & Tech Going Separate Directions: PFE, GOOGL, FB, LLY & More

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.

Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy

Even for rich nations with developed vaccination programs, that presents a host of problems ranging including building new databases to track who is getting the shot, working out ways to encourage mass uptake among younger people, ensuring adequate supply and running large-scale inoculation centers where the shots can be safely and quickly administered.

Pfizer Covid-19 Vaccine's next big challenge: giving it to enough people

Pfizer's Covid-19 vaccine could grab $15 billion in profit from a $100 billion market -- if it can answer five big questions

Pfizer Covid-19 Vaccine's Five Big Unknowns

Pfizer (PFE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Pfizer (PFE) in Focus: Stock Moves 7.7% Higher

Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.

2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine

Industries like entertainment, travel and hospitality, airlines, cruise ships, and casinos, were just a few of the sectors that reacted positively to the news.

Pfizer has a potential vaccine. Now what?

Early data from the vaccine's clinical trial shows it could be 90% effective at preventing the disease.

20 Million Doses Of Pfizer's Covid-19 Vaccine Headed To Spain In Early 2021

The 7 most important takeaways for investors.

These are the non-pharma winners and losers from the Pfizer vaccine results

Mylan

The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.

2 Best Pharma Stocks to Buy in November

Early results from phase 3 trial look promising but there are still many questions to be answered

Pfizer Covid vaccine: what has the trial found and is this a breakthrough?

Spain would get the first vaccines developed by U.S. pharmaceutical giant Pfizer in early 2021, Health Minister Salvador Illa said on Tuesday.

Spain to get first Pfizer vaccines in early 2021, Health Minister says

Dr. Anthony Fauci said Monday that Pfizer's coronavirus vaccine could be administered to people by the end of the year.

The New York Post: Pfizer COVID-19 vaccine could be given by the end of the year: Fauci

The Brazilian federal government is in talks with Pfizer Inc in Brazil to buy its experimental COVID-19 vaccine for inclusion in its national vaccination program, a spokesman for the company said on Monday.

Brazil in talks with Pfizer to buy promising COVID-19 vaccine

For the month of November thus far, the Dow has already climbed more than 10%.

Markets Rejoice Pfizer (PFE) Vaccine News

Kohl's

Macy's

Ross Stores

These four retailers are soaring today as an effective vaccine would help return the world, and shopping, to near-normal.

Vaccine Hope Sent These Retailers Soaring Monday

Lowe's

Trex

Zillow

The likelihood of a coronavirus vaccine has investors looking away from these companies, despite their great prospects.

Stocks Are Crushing It Today: Here's Why These 4 Stocks Fell

JPMorgan Chase & Co

M&T Bank

An effective vaccine in 2021 could get the economy churning at a more normal level and effectively help banks avoid some of the loan losses they are currently projecting.

News for Pfizer Stock (PFE)